Lexology July 12, 2024
Hogan Lovells

The U.S. Supreme Court has issued its highly anticipated decision overturning the 40-year old doctrine established in Chevron v. Natural Resources Defense Council, which recognized judicial deference to administrative agencies’ interpretations of ambiguous statutes under certain circumstances. The decision to eliminate Chevron deference is likely to place increased pressure on administrative agencies – including the Food and Drug Administration (FDA) – when interpreting and applying the law in instances where Congress was either unclear or left gaps, as such decisions may be open to increased scrutiny by the federal courts. Earlier this year, FDA Commissioner Robert Califf, MD, shared his concerns about the diminishing role of Chevron in recent years, and lamented the idea of judges stepping in and ”acting...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Pharma / Biotech, Regulations
Overturning Chevron Doctrine Could Impact Medicare’s Drug Selections For Price Negotiations
Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda
The financial burden of drug shortages: 7 study takeaways
What Stays True for U.S. Health Care Post #Election2024 (1) – Consumers’ Dissatisfaction with Drug Prices
Q&A: Generating data from neurons to teach AI the rules of the brain

Share This Article